The results indicated that a two-dose vaccination with GBP510/AS03 induced stronger neutralizing antibody and cell-mediated immune responses than ChAdOx1-S against the ancestral D614G strain 2 weeks after the second vaccination, sustained a favorable trend to GBP510/AS03 up to 6 months, and had a clinically acceptable safety profile up to 6 months after the second vaccination ( Song et al., 2023 ).
1
—
—